Abstract | Background/aim: Materials and methods: total of 51 consecutive patients with diagnosis of NPC were treated between February 2010 and December 2015. The median dose for PTV70 (range: 60–82) was given in 33 fractions (range: 31–35). Forty-five of the patients received concomitant weekly chemotherapy between 3–7 cycles (median 6). Eleven patients received neoadjuvant and thirty-nine patients received adjuvant chemotherapy. Results: At a median follow-up 43 months (range: 2–76) the estimated 5-year overall survival and disease-free survival were 74.6% and 62.6%, respectively. Conclusion:
|
Authors | Mehmet Faik Çetindağ, Atiye Yılmaz Özsavran, Bülent Yalçın, İclal Çetindağ, Ercan Karabekir, Şeyda Türkölmez, Dinçer Yeğen |
Journal | Turkish journal of medical sciences
(Turk J Med Sci)
Vol. 49
Issue 2
Pg. 558-565
(04 18 2019)
ISSN: 1303-6165 [Electronic] Turkey |
PMID | 30862133
(Publication Type: Journal Article)
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chemoradiotherapy
- Child
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Dose-Response Relationship, Radiation
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Nasopharyngeal Neoplasms
(mortality, pathology, radiotherapy, therapy)
- Radiotherapy, Intensity-Modulated
- Retrospective Studies
- Treatment Outcome
- Young Adult
|